King Pharma to lay off 20 percent

It's not just Big Pharma that's restructuring. King Pharmaceuticals plans to lay off 20 percent of its workforce and embark on a cost-cutting regime. The prompt: Possible loss of patent coverage on its Altace remedy for heart failure and high blood pressure. A U.S. Court of Appeals recently ruled against the company, but King has asked the judges to reconsider.

- check out King's release

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.